Zdrowie i gospodarka · 15/04/2026

Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments

The Food and Drug Administration (FDA) is hosting a public meeting to discuss the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments. The meeting is open to the public for comments and feedback.